Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medeon Biodesign's Other Operating Expense for the
three
months ended in Mar. 2026 was NT$0.0 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was NT$0.0 Mil.
Medeon Biodesign's quarterly Other Operating Expense
declined
from Sep. 2025 (NT$0.0 Mil) to Dec. 2025 (NT$-0.0 Mil) but then
increased
from Dec. 2025 (NT$-0.0 Mil) to Mar. 2026 (NT$0.0 Mil).
Medeon Biodesign's annual Other Operating Expense
increased
from Dec. 2023 (NT$-0.0 Mil) to Dec. 2024 (NT$0.0 Mil) and
increased
from Dec. 2024 (NT$0.0 Mil) to Dec. 2025 (NT$0.0 Mil).
Medeon Biodesign Other Operating Expense Related Terms
Medeon Biodesign Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Medeon Biodesign's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of NT$0.0 Mil mean?
Medeon Biodesign (ROCO:6499) has a Other Operating Expense of NT$0.0 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Medeon Biodesign and its competitors.
Is Medeon Biodesign's Other Operating Expense too high?
Medeon Biodesign's current Other Operating Expense is NT$0.0 Mil. Overall, Medeon Biodesign has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's Other Operating Expense compare to ISRG and BDX?
Medeon Biodesign's Other Operating Expense of NT$0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Devices & Instruments company?
A good Other Operating Expense depends on the Medical Devices & Instruments industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Medeon Biodesign and its competitors. Medeon Biodesign's current Other Operating Expense is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Possible Value Trap. The stock's GF Value™ is NT$107.27, compared to a current price of NT$66.80 — trading 37.7% below its estimated fair value. The current Other Operating Expense is NT$0.0 Mil. Medeon Biodesign's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current Other Operating Expense is NT$0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?
Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued.
The current stock price of NT$66.80 is trading 37.7% below its estimated GF Value™ of NT$107.27.
GuruFocus considers Medeon Biodesign to be Possible Value Trap.
Key valuation signals for ROCO:6499:
Other Operating Expense: NT$0.0 Mil
GF Value™: NT$107.27 vs. price of NT$66.80 (37.7% below fair value)
No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
66GF Score
Get the complete analysis for ROCO:6499
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6499 has been successfully added to your 
